1.南京中医药大学附属南京中医院,江苏省南京市秦淮区大明路157号,210022
2.南京中医药大学附属医院
3.南京中医药大学
4.南通大学
njyhm6502@163.com
收稿:2023-07-12,
修回:2024-01-10,
纸质出版:2024-04-02
移动端阅览
孔德松,赵峰,张彦亮等.翘芪组方治疗流行性感冒轻症患者36例有效性与安全性的随机对照试验[J].中医杂志,2024,65(07):710-715.
KONG Desong,ZHAO Feng,ZHANG Yanliang,et al.Effectiveness and Safety of Qiaoqi Formula (翘芪组方) for Mild Influenza: A 36-case Randomized Controlled Trial[J].Journal of Traditional Chinese Medicine,2024,65(07):710-715.
孔德松,赵峰,张彦亮等.翘芪组方治疗流行性感冒轻症患者36例有效性与安全性的随机对照试验[J].中医杂志,2024,65(07):710-715. DOI: 10.13288/j.11-2166/r.2024.07.009.
KONG Desong,ZHAO Feng,ZHANG Yanliang,et al.Effectiveness and Safety of Qiaoqi Formula (翘芪组方) for Mild Influenza: A 36-case Randomized Controlled Trial[J].Journal of Traditional Chinese Medicine,2024,65(07):710-715. DOI: 10.13288/j.11-2166/r.2024.07.009.
目的
2
观察翘芪组方治疗流行性感冒(流感)轻症的有效性与安全性。
方法
2
采用随机对照研究设计,收集流感轻症患者74例,随机分为试验组和对照组。试验组口服翘芪组方,每次40 ml,每天2次;对照组口服连花清瘟胶囊,每次1.4 g,每天3次。两组均连续治疗3天,治疗结束后连续访视4天。比较两组患者治疗后退热时间(包括退热起效时间,完全退热时间,24 h、48 h及72 h退热率),于治疗前及治疗后第4、7天比较两组中医证候总积分,于治疗后第7天评价中医证候疗效,并观察安全性指标,记录不良反应发生情况。
结果
2
最终纳入患者65例,其中试验组36例,对照组29例。试验组退热起效时间为(15.49±23.47)h、完全退热时间为(21.37±30.06)h、24 h退热率为77.14%、48 h退热率为88.57%、72 h退热率为91.42%,对照组以上指标分别为(17.58±20.38)h、(24.30±21.87)h、61.29%、90.32%、96.77%,两组比较差异均无统计学意义(
P
>0.05)。治疗后第7天两组中医证候总积分均较本组治疗前降低(
P
<0.05),但两组间中医证候疗效痊愈率、显效率、有效率、总有效率比较,差异均无统计学意义(
P
>0.05)。对照组患者治疗后第4天淋巴细胞比值高于本组治疗前(
P
<0.05),两组治疗后丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)、尿素、肌酐水平均在正常范围内。两组出现的主要不良反应为头痛和头晕,均为轻度,未发生严重不良反应。
结论
2
翘芪组方治疗流感轻症疗效与连花清瘟胶囊相当,均可缩短退热时间,改善临床症状,且研究过程中未发生严重不良反应,安全性较好。
Objective
2
To evaluate the effectiveness and safety of
Qiaoqi Formula
(翘芪组方) for mild influenza.
Methods
2
A randomized controlled study was designed, recruiting 74 patients with mild influenza, who were randomly divided into trial group and control group. The trial group took
Qiaoqi Formula
orally, 40ml each time, twice a day; the control group took
Lianhua Qingwen Capsules
(连花清瘟胶囊) orally, 1.4 g each time, three times a day. Both groups were treated for 3 consecutive days and follow-up for 4 consecutive days after treatment. The time for fever reduction including onset of fever reduction, complete fever reduction time, fever reduction rates at 24, 48 and 72 hours, improvement of influenza symptoms, total traditional Chinese medicine (TCM) symptom score, and safety indicators in two groups after treatment were recorded.
Results
2
Sixty-five patients were ultimately included, including 36 in the trial group and 29 in the control group. Onset time of fever reduction in the trial group was (15.49±23.47) h, the complete fever reduction time (21.37±30.06)h, and the 24 h, 48 h, 72 h, fever reduction rate was 77.14%, 88.57%, 91.42% respectively. The above indicators of the control group showed as (17.58±20.38)h, (24.30±21.87)h, 61.29%, 90.32%, 96.77% respectively, with no statistically significant differences (
P
>0.05). On the 7th day after treatment, the total score of TCM syndromes in trial group and control group decreased compared to those before treatment (
P
<0.05). There was no statistically significant difference in the cure rate, significant effective rate, effective rate, and total effective rate of TCM syndromes between groups (
P
>0.05). On the 4th day, the lymphocyte ratio of patients in the control group was higher than before treatment, while alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea, and creatinine of both groups before and after treatment were within the normal range. The main adverse reactions in both groups were mild headache and dizziness, and no serious adverse reactions observed.
Conclusion
2
The therapeutic effect of
Qiaoqi Formula
in treating mild influenza is equivalent to
Lianhua Qingwen Capsules
, which can shorten the fever reduction time, improve clinical symptoms, and no adverse events observed during the study.
吕菁君 , 赵光举 , 赵宏宇 , 等 . 成人流行性感冒诊疗规范急诊专家共识(2022版) [J]. 中国急救医学 , 2022 , 42 ( 12 ): 1013 - 1026 .
国家卫生和计划生育委员会 , 国家中医药管理局 . 流行性感冒诊疗方案(2018年版) [J]. 中国感染控制杂志 , 2018 , 17 ( 2 ): 181 - 184 .
中华人民共和国国家卫生健康委员会疾病预防控制局 . 2021年全国法定传染病疫情概况 [EB/OL].( 2022-04-22 )[ 2023-09-10 ]. http://www.nhc.gov.cn/jkj/s3578/202204/4fd88a291d914abf8f7a91f6333567e1.shtml http://www.nhc.gov.cn/jkj/s3578/202204/4fd88a291d914abf8f7a91f6333567e1.shtml .
袁明 , 孙蓉 , 刘长青 , 等 . 抗流感病毒药物研究进展 [J]. 赤峰学院学报(自然科学版) , 2020 , 36 ( 12 ): 48 - 53 .
李修元 , 刘林洁 , 敖素华 . 中医药治疗流行性感冒的研究进展 [J]. 西南医科大学学报 , 2022 , 45 ( 2 ): 181 - 184 .
杨晓明 , 张愉 , 王星辉 , 等 . 翘芪颗粒治疗流行性感冒临床效果分析 [J]. 交通医学 , 2021 , 35 ( 1 ): 51 - 53 .
国家卫生健康委办公厅 , 国家中医药管理局办公室 . 流行性感冒诊疗方案(2019年版) [J]. 中国病毒病杂志 , 2020 , 10 ( 3 ): 164 - 168 .
国家卫生健康委员会 . 流行性感冒诊疗方案(2018年版修订版) [J]. 传染病信息 , 2018 , 31 ( 6 ): 500 - 504 .
李杰 , 刑俊 , 陈晓虎 . 连花清瘟颗粒联合奥司他韦治疗流行性感冒(风热犯卫证)的疗效及对免疫功能的影响 [J]. 药物评价研究 , 2023 , 46 ( 5 ): 1072 - 1077 .
文世梅 , 陈云飞 , 刘华 . 计量资料非劣效临床试验样本量及把握度的计算与SAS程序实现 [J]. 中国临床药理学与治疗学 , 2013 , 18 ( 1 ): 51 - 54 .
郑筱萸 . 中药新药临床研究指导原则(试行) [M]. 北京 : 中国医药科技出版社 , 2002 : 119 - 123 .
邓玲 . 中医病证诊断疗效标准 [M]. 北京 : 中国医药科技出版社 , 2017 .
顾恪波 , 贺梅娟 . 浅议外感热病中的“内外合邪” [J]. 北京中医药 , 2009 , 28 ( 5 ): 353 - 355 .
吴有性 . 温疫论 [M]. 张志斌,整理.北京 : 人民卫生出版社 , 2007 : 9 .
李云 , 张誉腾 , 李钰昕 , 等 . 基于《中华医典》中医药治疗时行感冒的用药分析 [J]. 世界中医药 , 2022 , 17 ( 14 ): 2041 - 2045 .
林樫 , 章惠萍 , 周润津 , 等 . 基于国家专利的中药复方治疗流行性感冒的用药规律研究 [J]. 中药新药与临床药理 , 2022 , 33 ( 12 ): 1724 - 1732 .
刘伟 , 龚普阳 , 顾健 , 等 . 具解热抗炎、免疫调节作用的中药用于治疗新型冠状病毒肺炎(COVID-19)的探讨 [J]. 中药材 , 2020 , 43 ( 8 ): 2077 - 2083 .
张悦 , 黎晓蕾 , 李皓月 , 等 . 中药天然活性成分在流行性感冒疫苗免疫佐剂中的应用与前景 [J]. 中国中药杂志 , 2023 , 48 ( 22 ): 5985 - 5992 .
0
浏览量
5
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号